Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term update of the 24954 EORTC phase III trial on larynx preservation.
Henriques De Figueiredo B, Fortpied C, Menis J, Lefebvre JL, Barzan L, de Raucourt D, Geoffrois L, Giurgea L, Hupperets P, Leemans CR, Licitra L, Rolland F, Tesselaar M, Vermorken JB, Grégoire V; EORTC Head and Neck Cancer and Radiation Oncology Cooperative Groups. Henriques De Figueiredo B, et al. Among authors: fortpied c. Eur J Cancer. 2016 Sep;65:109-12. doi: 10.1016/j.ejca.2016.06.024. Epub 2016 Aug 2. Eur J Cancer. 2016. PMID: 27494036 Clinical Trial.
EORTC elderly task force position paper: approach to the older cancer patient.
Pallis AG, Fortpied C, Wedding U, Van Nes MC, Penninckx B, Ring A, Lacombe D, Monfardini S, Scalliet P, Wildiers H. Pallis AG, et al. Among authors: fortpied c. Eur J Cancer. 2010 Jun;46(9):1502-13. doi: 10.1016/j.ejca.2010.02.022. Epub 2010 Mar 12. Eur J Cancer. 2010. PMID: 20227872
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Psyrri A, Fortpied C, Koutsodontis G, Avgeris M, Kroupis C, Goutas N, Menis J, Herman L, Giurgea L, Remenár É, Degardin M, Pateras IS, Langendijk JA, van Herpen CML, Awada A, Germà-Lluch JR, Kienzer HR, Licitra L, Vermorken JB. Psyrri A, et al. Among authors: fortpied c. Ann Oncol. 2017 Sep 1;28(9):2213-2218. doi: 10.1093/annonc/mdx320. Ann Oncol. 2017. PMID: 28651338 Free article. Clinical Trial.
TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Specenier PM, Remenar E, Buter J, Schrijvers DL, Bergamini C, Licitra LF, Awada A, Clement PM, Fortpied C, Menis J, Vermorken JB. Specenier PM, et al. Among authors: fortpied c. Ann Oncol. 2017 Sep 1;28(9):2219-2224. doi: 10.1093/annonc/mdx300. Ann Oncol. 2017. PMID: 28911062 Free article. Clinical Trial.
Activity and safety of afatinib in a window preoperative EORTC study in patients with squamous cell carcinoma of the head and neck (SCCHN).
Machiels JP, Bossi P, Menis J, Lia M, Fortpied C, Liu Y, Lhommel R, Lemort M, Schmitz S, Canevari S, De Cecco L, Guzzo M, Bianchi R, Quattrone P, Crippa F, Duprez T, Lalami Y, Quiriny M, de Saint Aubain N, Clement PM, Coropciuc R, Hauben E, Licitra LF. Machiels JP, et al. Among authors: fortpied c. Ann Oncol. 2018 Apr 1;29(4):985-991. doi: 10.1093/annonc/mdy013. Ann Oncol. 2018. PMID: 29346507 Free article. Clinical Trial.
Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
Galot R, Le Tourneau C, Guigay J, Licitra L, Tinhofer I, Kong A, Caballero C, Fortpied C, Bogaerts J, Govaerts AS, Staelens D, Raveloarivahy T, Rodegher L, Laes JF, Saada-Bouzid E, Machiels JP. Galot R, et al. Among authors: fortpied c. Ann Oncol. 2018 Dec 1;29(12):2313-2327. doi: 10.1093/annonc/mdy452. Ann Oncol. 2018. PMID: 30307465 Free article. Review.
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis.
Petit C, Lacas B, Pignon JP, Le QT, Grégoire V, Grau C, Hackshaw A, Zackrisson B, Parmar MKB, Lee JW, Ghi MG, Sanguineti G, Temam S, Cheugoua-Zanetsie M, O'Sullivan B, Posner MR, Vokes EE, Cruz Hernandez JJ, Szutkowski Z, Lartigau E, Budach V, Suwiński R, Poulsen M, Kumar S, Ghosh Laskar S, Mazeron JJ, Jeremic B, Simes J, Zhong LP, Overgaard J, Fortpied C, Torres-Saavedra P, Bourhis J, Aupérin A, Blanchard P; MACH-NC and MARCH Collaborative Groups. Petit C, et al. Among authors: fortpied c. Lancet Oncol. 2021 May;22(5):727-736. doi: 10.1016/S1470-2045(21)00076-0. Epub 2021 Apr 13. Lancet Oncol. 2021. PMID: 33862002
Quality assurance of radiotherapy in the ongoing EORTC 1420 "Best of" trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure.
Stelmes JJ, Vu E, Grégoire V, Simon C, Clementel E, Kazmierska J, Grant W, Ozsahin M, Tomsej M, Vieillevigne L, Fortpied C, Hurkmans EC, Branquinho A, Andratschke N, Zimmermann F, Weber DC. Stelmes JJ, et al. Among authors: fortpied c. Radiat Oncol. 2021 May 1;16(1):81. doi: 10.1186/s13014-021-01809-2. Radiat Oncol. 2021. PMID: 33933118 Free PMC article.
Tumor Microenvironment Modifications Induced by Afatinib in Squamous Cell Carcinoma of the Head and Neck: A Window-of-Opportunity Study (EORTC-90111-24111).
Beyaert SP, Loriot AE, Huyghe ND, Goebbels RM, Mendola A, Govaerts AS, Fortpied C, Baldin P, Licitra LF, Lalami Y, Clement PM, Machiels JH, Schmitz S. Beyaert SP, et al. Among authors: fortpied c. Clin Cancer Res. 2023 Oct 13;29(20):4076-4087. doi: 10.1158/1078-0432.CCR-23-0645. Clin Cancer Res. 2023. PMID: 37531234
52 results